Gold is 2025’s best performer. UBS sees more upside
On Monday, Redburn-Atlantic initiated coverage on IQVIA Holdings (NYSE:IQV), a leading global clinical research organization (CRO), with a Buy rating and a price target set at $276.00. The firm recognized IQVIA as the largest CRO worldwide and a top provider of healthcare data, analytics, and consulting services to various stakeholders in the healthcare industry, including payors, providers, and the biopharmaceutical sector.
The coverage initiation comes with an optimistic outlook for IQVIA's future performance. Redburn-Atlantic highlighted that while there are common concerns regarding the growth of the CRO industry, they anticipate a rebound in the commercial aspect of IQVIA's business. This segment has previously experienced spending challenges, but it is now expected to contribute to a double-digit earnings increase in the fiscal year 2025.
IQVIA's prominent position in the market, combined with its comprehensive service offerings, positions the company favorably within the healthcare sector. The firm's expertise in delivering valuable insights and strategic guidance to its clients is instrumental for driving advancements in healthcare and pharmaceutical research and development.
The analyst's statement reflects confidence in IQVIA's capacity to overcome industry growth concerns. This is primarily due to the potential for a reacceleration in the commercial side of the business, which is anticipated to bolster earnings growth in the coming fiscal year.
In other recent news, IQVIA Holdings reported steady revenue growth in Q2 2024, with a year-over-year increase of 2.3%, reaching $3,814 million, and an 8.6% growth in adjusted diluted earnings per share. The company anticipates a revenue range between $15,425 million and $15,525 million for the year. RBC Capital initiated coverage on IQVIA with an Outperform rating, citing the company's unique data, technology, and extensive service offerings. Meanwhile, Mizuho Securities maintained its Outperform rating, highlighting the company's focus on internal investments and mergers and acquisitions. However, Jefferies adjusted its stance on IQVIA, shifting the rating from Buy to Hold and lowering the price target due to modest bookings increase and competitive pressures.
InvestingPro Insights
IQVIA Holdings' strong market position, as highlighted by Redburn-Atlantic, is further supported by InvestingPro data and tips. The company's market capitalization stands at $42.16 billion, underscoring its significant presence in the Life Sciences Tools & Services industry.
An InvestingPro Tip reveals that IQVIA has a perfect Piotroski Score of 9, indicating robust financial health and operational efficiency. This aligns well with Redburn-Atlantic's optimistic outlook on the company's future performance.
Another relevant InvestingPro Tip suggests that IQVIA is trading at a low P/E ratio relative to near-term earnings growth. This is reflected in the company's PEG ratio of 0.9 for the last twelve months as of Q2 2024, potentially indicating an undervalued stock relative to its growth prospects. This could support the analyst's Buy rating and price target of $276.00, especially considering that the InvestingPro Fair Value for IQVIA is estimated at $248.25.
IQVIA's revenue for the last twelve months as of Q2 2024 was $15.15 billion, with a revenue growth of 3.23% over the same period. This steady growth, coupled with the analyst's expectation of a rebound in the commercial aspect of IQVIA's business, suggests potential for the double-digit earnings increase projected for fiscal year 2025.
For investors seeking more comprehensive analysis, InvestingPro offers additional tips and insights on IQVIA Holdings, with 9 more tips available on the platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.